Furthermore, the present findings just indicate the critical role of NORAD knockdown in attenuating hypoxia-evoked CM and chemoresistance in vitro; nevertheless, whether targeting NORAD exerts the ideal anti-CRC efficacy in vivo. This evidence concerns the gene NORAD and colorectal carcinoma.